These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26003889)

  • 1. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
    Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
    Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
    Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Goodman M; Thurston H; Penman J
    Horm Metab Res; 2009 May; 41(5):368-73. PubMed ID: 19221978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
    Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
    Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
    Matthews DR; Dejager S; Ahren B; Fonseca V; Ferrannini E; Couturier A; Foley JE; Zinman B
    Diabetes Obes Metab; 2010 Sep; 12(9):780-9. PubMed ID: 20649630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
    Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
    Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
    Schweizer A; Couturier A; Foley JE; Dejager S
    Diabet Med; 2007 Sep; 24(9):955-61. PubMed ID: 17509069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
    Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
    Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.